This follows the immense popularity of injectible GLP1R drugs, such as Novo Nordisk (Wegovy and Saxenda), Eli Lilly (Zepbound), and Shanghai Benemae Pharmaceutical (Yishengtai), approved for obesity.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback